Virtus Biotech Clinical Trials ETF
18 hedge funds and large institutions have $7.19M invested in Virtus Biotech Clinical Trials ETF in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 6 reducing their positions, and 3 closing their positions.
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
2.57% less ownership
Funds ownership: 36.86% → 34.29% (-2.6%)
5% less funds holding
Funds holding: 19 → 18 (-1)
37% less capital invested
Capital invested by funds: $11.4M → $7.19M (-$4.18M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GRP
Global Retirement Partners
San Rafael,
California
|
+$12.1K |
| 2 |
MCC
Money Concepts Capital
Palm Beach Gardens,
Florida
|
+$6.51K |
| 3 |
ARMC
American Research & Management Company
Marion,
Massachusetts
|
+$2.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$379K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$279K |
| 3 |
LPL Financial
San Diego,
California
|
-$240K |
| 4 |
FTUS
Flow Traders U.S.
New York
|
-$223K |
| 5 |
Morgan Stanley
New York
|
-$23.6K |
BBC Hedge Fund Activity: Q1 2022 in Review
18 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q1 2022, worth a combined $7.19M — down 37% from $11.4M a quarter earlier.
Fund positioning in BBC was balanced in Q1 2022: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 6 trimmed.
The largest buyer was Global Retirement Partners, opening a new position worth an estimated $12.1K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $379K sold.
- 18 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q1 2022, down from 19 in Q4 2021.
- Funds reported $7.19M of Virtus Biotech Clinical Trials ETF stock for Q1 2022, down 37% quarter-over-quarter.
- 3 funds opened new Virtus Biotech Clinical Trials ETF positions in Q1 2022 and 3 closed out, a net change of 0 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q1 2022 was Global Retirement Partners, an estimated $12.1K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q1 2022 was Susquehanna International Group, an estimated $379K sold.
Based on aggregated 13F filings for Q1 2022.